» Articles » PMID: 15611238

Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation

Overview
Journal J Immunol
Date 2004 Dec 22
PMID 15611238
Citations 170
Authors
Affiliations
Soon will be listed here.
Abstract

The balance between regulatory and effector functions is important for maintaining efficient immune responses, while avoiding autoimmunity. The inflammatory skin disease psoriasis is sustained by the ongoing activation of pathogenic effector T cells. We found that a CD4(+) T lymphocyte subpopulation in peripheral blood, phenotypically CD25(high), CTLA-4(+), Foxp3(high) (regulatory T (Treg) cells), is deficient in its suppressor activity in psoriasis. This was associated with accelerated proliferation of CD4(+) responder T cells in psoriasis, the majority of which expressed CXCR3. Nevertheless, criss-cross experiments isolated the defect to psoriatic Treg cells. To examine Treg cells in a nonlymphoid tissue of a human T cell-mediated disease, Treg cells were also analyzed and isolated from the site of inflammation, psoriatic lesional skin. At the regulatory vs effector T cells ratios calculated to be present in skin, however, the psoriatic Treg cell population demonstrated decreased suppression of effector T cells. Thus, dysfunctional blood and target tissue CD4(+)CD25(high) Treg cell activity may lead to reduced restraint and consequent hyperproliferation of psoriatic pathogenic T cells in vivo. These findings represent a critical component of human organ-specific autoimmune disease and may have important implications with regard to the possible therapeutic manipulation of Treg cells in vivo.

Citing Articles

Roles for Exosomes in the Pathogenesis, Drug Delivery and Therapy of Psoriasis.

Chen Y, Liu H, He Y, Yang B, Lu W, Dai Z Pharmaceutics. 2025; 17(1).

PMID: 39861699 PMC: 11768235. DOI: 10.3390/pharmaceutics17010051.


The Role of Extracellular Vesicles in the Development and Treatment of Psoriasis: Narrative Review.

Tang B, Bi Y, Zheng X, Yang Y, Huang X, Yang K Pharmaceutics. 2025; 16(12.

PMID: 39771564 PMC: 11677080. DOI: 10.3390/pharmaceutics16121586.


Evaluation of CD4 CD25 CD127 Regulatory T-Cells in Different Stages of Psoriatic Arthritis Patients.

Safari R, Shakurnia A, Ghadiri A, Rajaei E, Mowla K, Haidari M Adv Biomed Res. 2024; 13:77.

PMID: 39512405 PMC: 11542692. DOI: 10.4103/abr.abr_359_23.


Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies.

Braga G, Francisco G, Bagatini M J Mol Med (Berl). 2024; 102(10):1187-1198.

PMID: 39212718 DOI: 10.1007/s00109-024-02481-1.


Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis.

Petrovic A, Samuelsen V, Davies R, Aarebrot A, Holmes T, Sarkar I Clin Exp Immunol. 2024; 218(3):329-340.

PMID: 39121030 PMC: 11557139. DOI: 10.1093/cei/uxae070.


References
1.
Itoh M, Takahashi T, Sakaguchi N, KUNIYASU Y, Shimizu J, Otsuka F . Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999; 162(9):5317-26. View

2.
Thornton A, Shevach E . Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 1999; 164(1):183-90. DOI: 10.4049/jimmunol.164.1.183. View

3.
Ferenczi K, Burack L, Pope M, Krueger J, Austin L . CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun. 2000; 14(1):63-78. DOI: 10.1006/jaut.1999.0343. View

4.
Salomon B, Lenschow D, Rhee L, Ashourian N, Singh B, Sharpe A . B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12(4):431-40. DOI: 10.1016/s1074-7613(00)80195-8. View

5.
Mrowietz U, Zhu K, Christophers E . Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol. 2000; 136(5):675-6. DOI: 10.1001/archderm.136.5.675. View